Discovery of 4-((3′<i>R</i>,4′<i>S</i>,5′<i>R</i>)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
作者:Angelo Aguilar、Jianfeng Lu、Liu Liu、Ding Du、Denzil Bernard、Donna McEachern、Sally Przybranowski、Xiaoqin Li、Ruijuan Luo、Bo Wen、Duxin Sun、Hengbang Wang、Jianfeng Wen、Guangfeng Wang、Yifan Zhai、Ming Guo、Dajun Yang、Shaomeng Wang
DOI:10.1021/acs.jmedchem.6b01665
日期:2017.4.13
with two identical substituents at the carbon-2 of the pyrrolidine core as potent MDM2 inhibitors. In this paper we describe an extensive structure–activity relationship study of this class of MDM2 inhibitors, which led to the discovery of 60 (AA-115/APG-115). Compound 60 has a very high affinity to MDM2 (Ki < 1 nM), potent cellular activity, and an excellent oral pharmacokinetic profile. Compound
我们以前曾报道过设计在螺吡咯烷核的碳2上具有两个相同取代基的螺硫醇作为有效的MDM2抑制剂。在本文中,我们描述了这类MDM2抑制剂的广泛的构效关系研究,从而发现了60种(AA-115 / APG-115)。化合物60对MDM2的亲和力非常高(K i <1 nM),有效的细胞活性以及出色的口服药代动力学特征。化合物60能够在体内实现完全持久的肿瘤消退,目前正处于癌症治疗的I期临床试验中。